Northwest Biotherapeutics (NWBO) Non-Current Deferred Tax Liability (2025 - 2026)
Northwest Biotherapeutics (NWBO) posted quarterly Non-Current Deferred Tax Liability of $12.9 million for Q1 2026, down 1.78% quarter-over-quarter from $13.2 million in Q4 2025.
Powered by 
Analysis
Northwest Biotherapeutics (NWBO) Non-Current Deferred Tax Liability (2025 - 2026) Analysis & Trends
Northwest Biotherapeutics' Non-Current Deferred Tax Liability history runs 2 years deep, the most recent figure standing at $12.9 million for Q1 2026.
- In Q1 2026, Non-Current Deferred Tax Liability changed N/A year-over-year to $12.9 million; the TTM figure through Mar 2026 stood at $12.9 million (changed N/A YoY), while the FY2025 annual figure was $13.2 million, changed N/A from the prior year.
- Non-Current Deferred Tax Liability for Q1 2026 stood at $12.9 million, down from $13.2 million in the prior quarter.
- The five-year high for Non-Current Deferred Tax Liability was $13.2 million in Q4 2025, with the low at $12.9 million in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Northwest Biotherapeutics | 278.23 Mn | 277.63 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 12.96 Mn |
| Mar 31, 2026 | 12.94 Mn |
| Dec 31, 2025 | 13.17 Mn |